The importance of maintaining responsible relationships between pharmaceutical companies and healthcare professionals (HCPs) has been put into focus by recent scandals involving major companies being investigated for alleged bribery practices and kickbacks as well as high-profile settlements in places from the US to China.
Exposure of this sort carries significant implications for firms' reputations and profitability locally and globally. In today's robust enforcement environment, it is more vital than ever for multinational companies to monitor and enforce compliance programmes to avoid legal exposure and minimise risks resulting from their personnel's involvement in unethical business behaviour.
The relationship between pharmaceutical manufacturers and HCPs is an interdependent and complex one. Manufacturers and HCPs have to work together in the development of products, from conducting clinical trials to pre-market testing.
This article is older than 60 days, which we reserve for our premium members only.You can subscribe to our premium member subscription, here.